Life Stem Genetics Current Assets
Current Assets of Life Stem Genetics (LIFS) as of Aug 16, 2026.
Get this data via API
Financial Data API
Current Assets
0.00USD
Last updated:
Current Assets of Life Stem Genetics is 2026 0.00 USD. Current Assets of Life Stem Genetics was 2025 0.00 USD. It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
Life Stem Genetics Stock analysis
What does Life Stem Genetics do? Life Stem Genetics Inc is a company specializing in regenerative medicine, specifically in the manufacturing and application of stem cell therapies. It was founded in 2012 by experienced scientists and entrepreneurs and has since become a leading provider of stem cell treatments.
The business model of Life Stem Genetics is based on the development and application of stem cell therapies that aim to regenerate diseased or injured tissues and organs. These therapies are utilized by specialized doctors and clinics worldwide to treat a variety of conditions and injuries, including degenerative diseases such as arthritis, osteoporosis, and Alzheimer's, as well as joint, muscle, and bone injuries.
The company operates in various sectors, each focusing on different aspects of regenerative medicine. One of these sectors is the research of new stem cell therapies and technologies, aiming to improve the effectiveness and efficiency of treatments. This includes the identification of new types of stem cells, the development of new cultivation techniques, and the optimization of procedures for stem cell transplantation.
Another sector of Life Stem Genetics is the production of stem cell products that can be used by doctors and clinics for patient treatment. This includes stem cell preparations for injection into the bloodstream or tissues, as well as freeze & thaw preparations used for long-term storage of stem cells.
In addition to research and production of stem cell therapies, Life Stem Genetics also offers consulting services for doctors and clinics interested in utilizing stem cell treatments. This includes training and workshops on stem cell therapy, support in setting up stem cell clinics, and expert opinions on specific application areas.
The products of Life Stem Genetics include various stem cell therapies tailored to the treatment of specific diseases and injuries. For example, the company offers stem cell therapies for the treatment of arthritis, spinal injuries, and diabetes. Furthermore, the company has also developed stem cell treatments specifically targeting the regeneration of skin tissue and hair follicles.
Overall, Life Stem Genetics is an innovative company in the field of regenerative medicine, contributing to the improvement of patients' lives worldwide through its research, production, and application of stem cell therapies. With its diverse product portfolio and extensive expertise in the selection and use of stem cells, the company is a significant player in this field and will continue to play an important role in the development of new therapies and treatment options in the future. Life Stem Genetics is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Life Stem Genetics stock
On Eulerpool you can find the complete historical development of Current Assets Life Stem Genetics since 2006 – with annual values, charts, and detailed analysis.
Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.
Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Life Stem Genetics historically and in real time.
Access this data via the Eulerpool API
Balance Sheet — Life Stem Genetics
Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets
All Key Metrics — Life Stem Genetics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth